Jüngste Beiträge
- Blinatumomab (BLINCYTO) Prescribing Information | Hong Kong Dengyue MedicineBLINCYTO® is the world’s first approved BiTE® immuno-oncology therapy, targeting the CD19 surface antigen on B cells. BiTE® molecules help the immune system detect and target malignant cells by bringing T cells—a type of white blood cell capable of killing cells recognized as threats—into contact with cancer cells. By positioning T cells near cancer cells, they can...0 Kommentare 0 Anteile 81 AnsichtenPlease log in to like, share and comment!
Mehr Artikel
DengYue Medicine (DengYueMed/Hong Kong Dengyue Pharmaceutical Limited), founded in 2019, is located in Hong Kong SAR. DengYue is licensed by the Department of Health of Hong Kong to take photos of pharmaceutical import and export wholesalers, specializing in the import and export of new and specialty drugs as well as isolated drugs in the field of major chronic diseases.